Want to see ADMA full AI Analyst Report?

ADMA Biologics (ADMA) Price & Analysis

3,037 Followers

ADMA Stock Chart & Stats

$11.01

-$0.24(-1.31%)

At close: Jan 08 4:00 PM EST

$11.01

-$0.24(-1.31%)

Day’s Range― - ―

52-Week Range$7.21 - $20.46

Previous CloseN/A

Volume407.39K

Average Volume (3M)3.38M

Market Cap

$1.94B

Enterprise Value$2.23K

Total Cash (Recent Filing)$138.15M

Total Debt (Recent Filing)$204.41M

Price to Earnings (P/E)12.1

Beta0.90

Next Earnings

Aug 12, 2026

EPS Estimate

0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.69

Shares Outstanding231,772,720

10 Day Avg. Volume2,769,217

30 Day Avg. Volume3,379,697

Financial Highlights & Ratios

PEG Ratio-1.09

Price to Book (P/B)9.11

Price to Sales (P/S)8.52

P/FCF Ratio156.23

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda<0.01

Forecast

1Y Price Target

$18.67

Price Target Upside69.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)0.8

Revenue Forecast (FY)$534.20M

Bulls Say, Bears Say

Bulls Say

ASCENIV Growth And AdoptionSustained double-digit ASCENIV growth and record new patient starts indicate durable product adoption in a specialty niche. This shifts mix toward higher-margin, branded therapy revenue, reducing reliance on commoditized IG sales and creating a structural growth engine for the business.

High And Expanding MarginsMaterial margin expansion reflects favorable product mix and yield-enhanced manufacturing. Persistently higher gross and net margins support cash generation, fund R&D and strategic initiatives, and provide resiliency against pricing pressure in commoditized segments over the medium term.

Improving Cash Generation & LiquidityStrong cash conversion and a meaningful cash balance improve financial flexibility and reduce dependency on external financing. Reliable cash generation enables reinvestment in pipeline (SG-001), opportunistic share repurchases, and supports working capital through industry cycles.

Bears Say

Standard IG Pricing PressureStructural discounting among new standard IG entrants can permanently depress ASPs for commoditized products. Continued ASP erosion undermines revenue and margin sustainability in the standard IG business, reducing diversification benefits and forcing strategic tradeoffs in pricing or investment.

BIVIGAM Volume CollapseA >50% year-over-year decline shows structural vulnerability of legacy product lines to distributor ordering shifts and competitive rebate dynamics. Persistent weakness in BIVIGAM reduces product diversification, heightens reliance on ASCENIV, and raises execution risk for stabilizing legacy revenues.

Elevated Working Capital And DSOsHigher DSOs and elevated channel inventory tie up cash and increase financing sensitivity. If collection and ordering normalization is delayed, prolonged working capital drag could constrain reinvestment, limit operational flexibility, and amplify liquidity risk despite current cash balances.

ADMA Biologics News

Adma Biologics price target lowered to $17 from $20 at Mizuho

Mizuho lowered the firm’s price target on Adma Biologics (ADMA) to $17 from $20 and keeps an Outperform...

10d ago

ADMA

ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff Deadline in ADMA BIOLOGICS, INC. Securities Class Action – Contact Levi & Korsinsky

ADMA Biologics allegedly shipped unwanted ASCENIV inventory to distributors at $900/gram, creating fictitious demand while payors denied reimbursement...

10d ago

ADMA

ADMA: Buy Rating Reiterated on Strong IG Product Momentum, Conservative Expectations and Unchanged $18 Price Target

ADMA Biologics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Gary Nachman from...

1M ago

ADMA

Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($NTR) ), ( ($CAVA) ), ( ($CBRL) ), ( ($ADMA)...

1M ago

NTR

ADMA

Adma Biologics resumed with an Outperform at Raymond James

Raymond James analyst Ryan Deschner resumed coverage of Adma Biologics (ADMA) with an Outperform rating and $21 price...

1M ago

ADMA

ADMA Biologics Shareholders Back Board, Auditor and Pay

ADMA Biologics ( ($ADMA) ) has provided an update. ADMA Biologics, Inc. held its 2026 Annual Meeting of...

2M ago

ADMA

ADMA Biologics Earnings Call: ASCENIV Fuels Profits

ADMA Biologics Inc (($ADMA)) has held its Q1 earnings call. Read on for the main highlights of the...

3M ago

ADMA

Adma Biologics price target lowered to $20 from $24 at Mizuho

Mizuho analyst Anthony Petrone lowered the firm’s price target on Adma Biologics (ADMA) to $20 from $24 and...

3M ago

ADMA

Adma Biologics price target lowered to $18 from $21 at Canaccord

Canaccord analyst Gary Nachman lowered the firm’s price target on Adma Biologics (ADMA) to $18 from $21 and...

3M ago

ADMA

Adma Biologics options imply 12.3% move in share price post-earnings

Pre-earnings options volume in Adma Biologics (ADMA) is 2.5x normal with calls leading puts 10:3. Implied volatility suggests...

3M ago

ADMA

Adma Biologics reports Q1 EPS 19c, consensus 20c

Reports Q1 revenue $114.49M, consensus $139.97M. “During the first quarter, the market for U.S. plasma derived therapies and...

3M ago

ADMA

Adma Biologics sees FY26 revenue $530M-$560M, consensus $629.1M

Sees FY26 adjusted EBITDA $265M-$300M. Grossman continued, “We believe the first quarter results likely represent a trough revenue...

3M ago

ADMA

Analyst Reaffirms Buy Rating on ADMA Biologics, Citing Expanded Asceniv FDA Label and Strong Growth Outlook Despite Bivigam Concerns

Canaccord Genuity analyst Gary Nachman maintained a Buy rating on ADMA Biologics today and set a price target...

3M ago

ADMA

Adma Biologics announces FDA approval for Asceniv sBLA

Adma Biologics (ADMA) announced the FDA has approved the company’s supplemental biologics license application submitted under section 351...

3M ago

ADMA

ADMA FAQ

What was ADMA Biologics Inc’s price range in the past 12 months?

ADMA Biologics Inc lowest stock price was $7.21 and its highest was $20.46 in the past 12 months.

What is ADMA Biologics Inc’s market cap?

ADMA Biologics Inc’s market cap is $1.94B.

When is ADMA Biologics Inc’s upcoming earnings report date?

ADMA Biologics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 18 days.

How were ADMA Biologics Inc’s earnings last quarter?

ADMA Biologics Inc released its earnings results on May 06, 2026. The company reported $0.171 earnings per share for the quarter, missing the consensus estimate of $0.193 by -$0.022.

Is ADMA Biologics Inc overvalued?

According to Wall Street analysts ADMA Biologics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ADMA Biologics Inc pay dividends?

ADMA Biologics Inc does not currently pay dividends.

What is ADMA Biologics Inc’s EPS estimate?

ADMA Biologics Inc’s EPS estimate is 0.17.

How many shares outstanding does ADMA Biologics Inc have?

ADMA Biologics Inc has 231,772,720 shares outstanding.

What happened to ADMA Biologics Inc’s price movement after its last earnings report?

ADMA Biologics Inc reported an EPS of $0.171 in its last earnings report, missing expectations of $0.193. Following the earnings report the stock price went down -15.972%.

Which hedge fund is a major shareholder of ADMA Biologics Inc?

Currently, no hedge funds are holding shares in ADMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ADMA Biologics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

30.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ADMA Biologics Inc

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.

ADMA Biologics (ADMA) Earnings & Revenues

Historic Earnings Reports

ADMA Stock 12 Month Forecast

Average Price Target

$18.67

▲(69.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","10":"$10","14":"$14","18":"$18","22":"$22"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,10,14,18,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.61,9.563076923076922,10.516153846153845,11.46923076923077,12.422307692307692,13.375384615384615,14.32846153846154,15.281538461538462,16.234615384615385,17.18769230769231,18.14076923076923,19.093846153846155,20.04692307692308,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.61,9.383589743589743,10.157179487179487,10.93076923076923,11.704358974358973,12.477948717948717,13.251538461538459,14.025128205128203,14.798717948717947,15.57230769230769,16.345897435897434,17.119487179487177,17.89307692307692,{"y":18.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.61,9.255384615384616,9.90076923076923,10.546153846153846,11.19153846153846,11.836923076923076,12.482307692307693,13.127692307692307,13.773076923076923,14.418461538461539,15.063846153846153,15.70923076923077,16.354615384615386,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.52,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >